The clinical operation team kept in touch with each site and coordinated with colleagues from medical science, pharmacovigilance, quality assurance as well as related responsible personnel from CRO/SMO, to conduct active discussion about the different types of visit arrangement, safe and rational drug use and more frequent dialogues between patients and sites. All the investigators worked together to develop action plans, ensuring patients' medication safety and promoting rational drug use.

Alpha Biopharma guaranteed patients of their normal treatment and clinical trial quality during the outbreak. In addition, we were very concerned about the protection of the related personnel (CRC/CRA) who carried out clinical trials on the front line. We purchased a certain number of medical masks, hand sanitizers, effervescent tablets, goggles, protective clothing and other resources (a total of 3,000 sets) through different channels, and sent them to 41 sites involved in the clinical trials across China as soon as possible to ensure the smooth daily work of each front-line staff.